Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0169

Congress meeting · Dr. Benedikt Castellano

08 Jan 2026 · Virtual · Dr. Benedikt Castellano, National Cancer Center Tokyo · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0169—

Capture insight from this engagement

Location: National Cancer Center Tokyo
Therapeutic area: Neurology
Country: Japan
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Dosing in hepatic impairment
Chronic migraine data

Scientific content used

CGRP class review
Chronic migraine scientific platform

Questions raised

What is the persistence rate at 18 months in real-world cohorts?
Is there guidance on switching from a monoclonal antibody?

Notes

Congress meeting with headache specialist at National Cancer Center Tokyo. Discussed dosing in hepatic impairment, chronic migraine data.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0169

Audit history (0)

All create, update and approval events for this record

No audit events in sample data